|1.||Lip, Gregory Y H: 88 articles (10/2015 - 08/2002)|
|2.||Angiolillo, Dominick J: 67 articles (01/2016 - 05/2004)|
|3.||Bhatt, Deepak L: 64 articles (08/2015 - 06/2002)|
|4.||Park, Choon-Sik: 62 articles (07/2015 - 09/2004)|
|5.||Park, Hae-Sim: 53 articles (06/2015 - 02/2003)|
|6.||Gurbel, Paul A: 46 articles (12/2015 - 06/2002)|
|7.||Chan, Andrew T: 44 articles (01/2016 - 06/2003)|
|8.||Eikelboom, John W: 43 articles (02/2015 - 04/2002)|
|9.||Yusuf, Salim: 43 articles (12/2014 - 04/2002)|
|10.||Hart, Robert G: 42 articles (07/2015 - 10/2002)|
04/01/1999 - "Future studies should include an examination of those agents that have previously demonstrated efficacy in secondary stroke prevention, most notably, aspirin. "
01/01/2012 - "Currently, the best treatment for ICAD remains aspirin therapy, but many patients who are placed on aspirin continue to experience recurrent strokes. "
10/01/2000 - "Using the best estimate of the efficacy of aspirin to prevent first-time stroke and MI, PTOT and DA treatment recommendations whether or not to take aspirin were discordant for 38% of participants (16 of 42) (p < 0.001). "
10/01/2000 - "Finally, based on these treatment thresholds, using the best estimates of the efficacy of aspirin to prevent first-time stroke and MI, PTOT and DA treatment recommendations for individual participants were compared. "
06/01/2000 - "There was a highly significant reduction of 7 per 1000 (SD 1) in recurrent ischemic stroke (320 [1.6%] aspirin versus 457 [2. 3%] control, 2P<0.000001) and a less clearly significant reduction of 4 (SD 2) per 1000 in death without further stroke (5.0% versus 5. 4%, 2P=0.05). "
12/01/1996 - "Women who benefited the most from aspirin therapy were older, diabetic, symptomatic, or had a previous myocardial infarction. "
08/01/2004 - "A meta-analysis of randomized trials has shown a significant reduction of mortality rate in patients receiving aspirin for secondary prevention after acute myocardial infarction (AMI). "
11/01/2001 - "At the start of the eighties, in the wake of the good results obtained with aspirin in secondary prevention, two studies were launched aimed at testing the effect of aspirin on the primary prevention of myocardial infarction. "
02/15/1980 - "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period. "
08/01/2014 - "After PCI, both groups showed a statistically significant reduction in corrected Thrombolysis In Myocardial Infarction frame count more evident in aspirin reload group (P=0.0023). "
04/01/2004 - "The percent maximum protection against thermal pain produced by Aspirin (71.43%) was twice as high as that produced by the most active of the four derivatives (43.65%). "
01/01/1981 - "Pain, the most prominent symptom, is often nocturnal and is relieved by aspirin in 30 to 40% of patients. "
11/01/2012 - "Once diagnosed, an antalgic treatment by aspirin is well known to be very effective in relieving pain. "
04/01/2009 - "For the management of common disorders producing short-lasting pain, there is very good evidence of the efficacy of aspirin. "
09/01/2014 - "This study suggests that aspirin may be a beneficial treatment for VM, with a reduction in pain and soft tissue swelling and an acceptable side-effect profile, but the retrospective nature of the study and the small size of the cohort limited our conclusions. "
01/01/2012 - "It follows that most treatment guidelines advocate the use of the lowest aspirin dose effective in preventing thrombotic complications to minimize the risk of major bleeding. "
04/01/2014 - "In randomized trials, low-dose (LD) and high-dose (HD) aspirin (ASA) are equally effective in reducing ischemic complications, but HD ASA is associated with an increased risk of bleeding in the setting of dual antiplatelet therapy after percutaneous coronary intervention (PCI). "
03/30/2013 - "Use of clopiogrel without aspirin was associated with a significant reduction in bleeding complications and no increase in the rate of thrombotic events. "
01/01/2013 - "For patients with polycythaemia vera who have no clear indication or contraindication to aspirin therapy, available evidence suggests that the use of low-dose aspirin, when compared with no treatment, is associated with a statistically non-significant reduction in the risk of fatal thrombotic events and all-cause mortality, without an increased risk of major bleeding."
11/01/2012 - "For aspirin to be beneficial for an individual patient, the risk of a future CVD event must be large enough to outweigh the risk of bleeding. "
05/01/1999 - "Aspirin-treated blood perfused under normoxic conditions showed a marked decrease in thrombus with a concomitant increase in both platelet adhesion and covered surface percentages. "
08/15/2009 - "Aspirin reaction units were significantly greater in the DES thrombosis population. "
01/01/1997 - "These investigations created a favorable scenario for launching a European collaborative clinical trial (ECLAP study) aimed at testing the efficacy of low-dose aspirin in preventing thrombosis and prolonging survival in patients with PV."
08/04/2015 - "If left untreated both microvascular and major thrombosis frequently do occur in MPN-T, but can easily be cured and prevented by low dose aspirin as platelet counts are above 350 × 10(9)/L. "
07/01/2012 - "General lack of TF expression by neoplastic plasma cells may explain why thrombosis is not predictive of poor outcome, and why aspirin prophylaxis is often effective in MM."
|5.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|8.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|9.||Aspirin (Acetylsalicylic Acid)